Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part Study (Open-label Followed by Double-blind, Randomized, Placebo-controlled, Parallel Group) of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Subjects With Bipolar I/II Disorder With a Current Major Depressive Episode

NCT03692910 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03692910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03692910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part Study (Open-label Followed by Double-blind, Randomized, Placebo-controlled, Parallel Group) of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Subjects With Bipolar I/II Disorder With a Current Major Depressive Episode
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
August 23, 2018
Completion date
May 21, 2019
Enrollment
35 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder i, bipolar disorder ii, major depressive episode